|
|
| "Pursuing partnering and licensing opportunities
at various pre-clinical and clinical testing stages" |
| |
|
|
Enlyton is drawing from the collective resource skills of its clinicians and scientists in the discovery, development and validation of novel imaging and detection tools for diagnostic and prognostic applications in the treatment of cancer. Enlyton’s first proposed targeting agent (ATA-1) has demonstrated promise for use in PET/CT; the patient population to be addressed is well understood; the need for better diagnostic information is clear; and the proposed solutions offer the prospect of providing better patient treatment outcomes.
Enlyton will pursue partnering and licensing opportunities at various pre-clinical and clinical testing stages as the means to finance expanded clinical trials, regulatory approval and commercialization. We understand that collaboration considerations are based on the commercial promise of our technology and the strength of its strategic fit with appropriate partner prospects.
Contact Us
Corporate Headquarters:
Enlyton, Ltd.
7700 Rivers Edge Drive
Columbus, OH 43235
|